This is an open label 6 month pilot study for male and female participants over the age of 52 that desire treatment and prevention of senile purpura of the forearms. This study will be evaluating the effects of Adapalene 0.3% for the use in the treatment and prevention of senile purpura.
This is a new potential use for the product Adapalene 0.3%, which is currently an FDA approved topical treatment used for the treatment of acne. Senile purpura is a common sign of aging that appears in the form of dark blotches on the skin and is caused by bruising. Older adults tend to be more prone to bruising, since as people age, their skin becomes thinner and more fragile.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
Multispecialty Aesthetic Clinical Research Organization
Woodland Hills, California, United States
RECRUITINGMultispecialty Aesthetic Clinical Research Organization
Woodland Hills, California, United States
RECRUITINGShow the clinical benefit of daily application of Adapalene 0.3% in decreasing the signs of senile purpura
To evaluate and document the degree of aesthetic results of subjects with senile purpura using the MACRO MD Purpura Lesion Assessment Scale
Time frame: Up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.